Medicare GLP-1 Bridge Program: Who Qualifies for $50 Access to GLP1s like Wegovy and Zepbound

Program Overview: The Medicare GLP-1 Bridge program is a temporary CMS initiative operating outside of standard Medicare Part D insurance from July 1, 2026, through December 31, 2027. The new program provides selected anti-obesity medications—specifically Wegovy, Zepbound KwikPen, and Foundayo for a $50 monthly copay to qualifying Medicare members with a BMI of 35.0 or higher or a BMI of 27.0 to 34.9 combined with specific documented comorbidities.

This low-cost access targets a specific subpopulation of Medicare beneficiaries who meet strict age, plan enrollment, and clinical Body Mass Index (BMI) pathways. While the program operates independently of standard insurance structures, meaning the $50 payment does not count toward annual Part D deductibles or out-of-pocket thresholds. The Kaiser Family Foundation (KFF) estimates that 3.8 million Part D members meet the medical criteria required to qualify for the Bridge Program.

Covered vs. Excluded Medications

The Medicare GLP-1 Bridge program covers three specific brand-name options for weight management:

1. Foundayo tablets

2. Wegovy injections and tablets

3. Zepbound KwikPen

Exclusion Warning: Zepbound single-dose pens and vials are excluded from coverage. Diabetes-specific formulations—including Ozempic, Mounjaro, and Rybelsus—are excluded from the Bridge program because these formulations remain under standard Part D plan rules.

If a Medicare member requires a GLP-1 drug for a Part D-eligible medical condition, the claim must be processed through standard insurance rather than the Bridge program.

Part D-covered uses include the following medical conditions:

• Type 2 diabetes treatment.

• Moderate-to-severe obstructive sleep apnea in adults with obesity.

• Noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with liver scarring.

• Cardiovascular risk reduction in adults with established heart disease and a BMI over 27.

Who’s Eligible for $50 monthly GLP-1 copays? 

To qualify for the Bridge program, an individual must satisfy four distinct sets of criteria. A prescriber must verify these medical details through a prior authorization form.

Insurance Plan Enrollment

Medicare members must hold active enrollment in one of these qualifying plans:

• A stand-alone Medicare Part D prescription drug plan

• A Medicare Advantage plan (HMO, HMO-POS, or PPO) that includes Part D drug benefits.

• A qualifying Special Needs Plan (SNP) or employer/union-sponsored group health plan.

• The Limited Income Newly Eligible Transition (LI NET) program.

Note: Programs of All-Inclusive Care for the Elderly (PACE) and private fee-for-service plans are excluded.

Supervised Lifestyle Program

The GLP1 prescription must be part of an ongoing, medically supervised weight-management strategy that incorporates diet and exercise.

Age and Clinical BMI Tiers
Program applicants must be at least 18 years old.

Medical eligibility is divided into three distinct clinical tiers based on Body Mass Index (BMI) at the start of treatment:

Clinical Eligibility Tiers

Clinical Eligibility Tiers Coverage Continuity Rule: If a participant's BMI drops below the initial entry threshold after starting therapy, the participant maintains eligibility. The prescriber must document that the medical records verified the eligibility criteria at the exact start of the GLP-1 treatment.

2026 Prescription History

You generally cannot use the Bridge if you already receive a GLP-1 medication through your Medicare Part D plan. Continue obtaining the medication through the Part D plan unless Medicare or the prescriber confirms a different coverage path.

How the Bridge Program’s Financial System Works

The $50 copay applies to 28-day or 30-day supplies. Sixty-day and 90-day maintenance fills are unavailable under this program. Because the Bridge operates independently of federal Medicare Part D, specific financial restrictions apply:

• The $50 payment does not reduce a beneficiary’s standard Part D deductible.

• Copays do not accumulate toward the annual Part D out-of-pocket maximum.

• Medicare members cannot use the Medicare Prescription Payment Plan to spread costs into monthly installments.

• Low-Income Subsidy (Extra Help) discounts do not reduce the $50 copay rate.

• Manufacturer copay cards and commercial drug coupons cannot combine with Bridge program claims.

Humana serves as the central administrative processor for the Bridge program on behalf of the Centers for Medicare & Medicaid Services (CMS). Humana manages prior authorizations, coverage determinations, and pharmacy reimbursements.

What to Expect at the Pharmacy Counter

1. Action Needed: Prior Authorization: When the pharmacy runs the first prescription, the system will show a temporary status hold until prior authorization is confirmed.

2. Clinical Submission: The pharmacy notifies the prescriber, who must submit a clinical criteria form to Humana.

3. 72-Hour Review: Humana issues an approval or denial decision within 72 hours of receiving the completed provider paperwork.

After the first fill is approved, refills of the same covered drug do not require another prior authorization, even if the dose changes. A new authorization is required when the patient switches to a different covered GLP-1 medication.

Program Background and Future Outlook

Many individuals cannot afford the high costs of GLP1 medications. In a November 2025 KFF survey, 56% of adults using a GLP-1 medication reported difficulty affording their monthly prescriptions, and 14% stopped therapy due to costs.

The Medicare Bridge program acts as an interim safety net through December 31, 2027. CMS extended the Bridge after deciding not to launch the Medicare Part D portion of the BALANCE Model in 2027. CMS may use Bridge utilization data when considering future approaches, but Medicare coverage after December 2027 has not been established.

For eligibility questions, individuals should call 1-800-MEDICARE (1-800-633-4227) instead of their Plan D provider.

This article is for general informational purposes and reflects Medicare GLP-1 Bridge program guidance available as of July 1, 2026. Program rules, covered medications, eligibility criteria, and costs may change.